{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:34:29Z","timestamp":1791290069902,"version":"4.3.0"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Iron is a fundamental element for biological life, from bacteria to humans. Iron is essential for cell function and survival, energy production and metabolism, whereas increased levels cause oxidative stress. It is also a constituent of haemoglobin and thus it is necessary for oxygen transportation through the body. Given these multiple functions, the regulation of iron metabolism is complex and tight coupled with oxygen homeostasis at tissue and cellular levels, thanks to the interaction with the hypoxia inducible factor system. In patients with chronic kidney disease (CKD), iron deficiency significantly contributes to anaemia development. This frequently overlaps with chronic inflammation, causing iron- restricted erythropoiesis. To add further complexity, metabolic hyperferritinemia may, on one hand, increase the risk for CKD and, on the other, overlaps with functional iron deficiency. Excessive intracellular iron in certain cell types during CKD can also mediate cellular death (called ferroptosis), and contribute to the pathogenesis of kidney damage, atherosclerosis and vascular calcifications. This review is aimed at broadening the perspective of iron metabolism in the setting of CKD not just as a contributor to anaemia in CKD patients, but also as an important player with an impact on cell metabolism, renal fibrosis and the cardiovascular system.<\/jats:p>","DOI":"10.1093\/ndt\/gfae095","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T21:48:30Z","timestamp":1713995310000},"page":"1404-1415","source":"Crossref","is-referenced-by-count":25,"title":["Iron biology"],"prefix":"10.1093","volume":"39","author":[{"given":"Lucia","family":"Del Vecchio","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Sant'Anna Hospital , ASST Lariana, Como 22100 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Girelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Internal Medicine, University of Verona , Verona , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vinchi","sequence":"additional","affiliation":[{"name":"Iron Research Laboratory, Lindsley Kimball Research Institute, New York Blood Center , NY , USA"},{"name":"Department of Pathology and Laboratory Medicine , Weill Cornell Medicine, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Elliott","sequence":"additional","affiliation":[{"name":"Elliott Consulting , Thousand Oaks, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-2123","authenticated-orcid":false,"given":"Patrick B","family":"Mark","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-0345","authenticated-orcid":false,"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation , Universit\u00e0 degli Studi di Milano, Milan , Italy"},{"name":"Precision Medicine, Biological Resource Center Unit, Department of Transfusion Medicine, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Qian","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences and Gerald Choa Neuroscience Centre, Faculty of Medicine, The Chinese University of Hong Kong , Shatin, NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Medicine, Shanghai University , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Ming","family":"Qian","sequence":"additional","affiliation":[{"name":"Institute of Translational & Precision Medicine, Nantong University , Nantong , JS, China"},{"name":"Laboratory of Neuropharmacology, Fudan University , Shanghai ; , Shanghai , China"},{"name":"School of Pharmacy , Shanghai ; , Shanghai , China"},{"name":"and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University , Shanghai ; , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-261X","authenticated-orcid":false,"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis , , ASST Lecco, Lecco , Italy"},{"name":"(Past Director) Alessandro Manzoni Hospital , , ASST Lecco, Lecco , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"2024083002381189000_bib1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"key":"2024083002381189000_bib2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/cells12121581","article-title":"The role of inflammation in CKD","volume":"12","author":"Kadatane","year":"2023","journal-title":"Cells"},{"key":"2024083002381189000_bib3","doi-asserted-by":"crossref","first-page":"1240679","DOI":"10.3389\/fimmu.2023.1240679","article-title":"Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology","volume":"14","author":"Mazzarino","year":"2023","journal-title":"Front Immunol"},{"key":"2024083002381189000_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/17.suppl_11.39","article-title":"Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines","volume":"17","author":"Macdougall","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2024083002381189000_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","article-title":"Mechanisms controlling cellular and systemic iron homeostasis","volume":"25","author":"Galy","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024083002381189000_bib6","first-page":"613","article-title":"Hepcidin levels in chronic hemodialysis patients: a critical evaluation","volume-title":"Clin Chem Lab Med","author":"Valenti","year":"2014"},{"key":"2024083002381189000_bib7","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"key":"2024083002381189000_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41574-023-00807-6","article-title":"Consensus statement on the definition and classification of metabolic hyperferritinaemia","volume":"19","author":"Valenti","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2024083002381189000_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.03.014","article-title":"Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD","volume":"75","author":"Corradini","year":"2021","journal-title":"J Hepatol"},{"key":"2024083002381189000_bib10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/jdi.14011","article-title":"Independent risk factors of rapid glomerular filtration rate decline in patients with type 2 diabetes with preserved kidney function and normoalbuminuria: a multicenter cohort study","volume":"14","author":"Hirano","year":"2023","journal-title":"J Diabetes Investig"},{"key":"2024083002381189000_bib11","doi-asserted-by":"crossref","first-page":"892811","DOI":"10.3389\/fendo.2022.892811","article-title":"Association between iron metabolism and acute kidney injury in critically ill patients with diabetes","volume":"13","author":"Mo","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024083002381189000_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2024083002381189000_bib13","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"2024083002381189000_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41569-022-00735-4","article-title":"The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease","volume":"20","author":"Fang","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2024083002381189000_bib15","first-page":"6286984","article-title":"Pretreatment with roxadustat (FG-4592) attenuates folic acid-induced kidney injury through antiferroptosis via akt\/GSK-3\u03b2\/Nrf2 pathway","volume":"2020","author":"Li","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"2024083002381189000_bib16","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1172\/JCI72267","article-title":"Cellular and molecular mechanisms in kidney fibrosis","volume":"124","author":"Duffield","year":"2014","journal-title":"J Clin Invest"},{"key":"2024083002381189000_bib17","doi-asserted-by":"crossref","first-page":"e159235","DOI":"10.1172\/jci.insight.159235","article-title":"Iron therapy mitigates chronic kidney disease progression by regulating intracellular iron status of kidney macrophages","volume":"8","author":"Patino","year":"2023","journal-title":"JCI Insight"},{"key":"2024083002381189000_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","article-title":"Oxidative stress in chronic kidney disease","volume":"34","author":"Daenen","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2024083002381189000_bib19","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(81)92463-6","article-title":"Iron and the sex difference in heart disease risk","volume":"1","author":"Sullivan","year":"1981","journal-title":"Lancet"},{"key":"2024083002381189000_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.mehy.2013.12.013","article-title":"Hereditary hemochromatosis, iron, hepcidin, and coronary heart disease","volume":"82","author":"Mascitelli","year":"2014","journal-title":"Med Hypotheses"},{"key":"2024083002381189000_bib21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.ATV.0000128849.12617.f4","article-title":"Atherosclerosis in the apolipoprotein-E-deficientmouse: a decade of progress","volume":"24","author":"Meir","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024083002381189000_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fphar.2014.00094","article-title":"Atherogenesis and iron: from epidemiology to cellular level","volume":"5","author":"Vinchi","year":"2014","journal-title":"Front Pharmacol"},{"key":"2024083002381189000_bib23","doi-asserted-by":"crossref","first-page":"857933","DOI":"10.3389\/fcvm.2022.857933","article-title":"The role of iron in atherosclerosis in apolipoprotein E deficient mice","volume":"9","author":"Ma","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024083002381189000_bib24","doi-asserted-by":"crossref","first-page":"116702","DOI":"10.1016\/j.lfs.2019.116702","article-title":"Chronic iron overload intensifies atherosclerosis in apolipoprotein E deficient mice: role of oxidative stress and endothelial dysfunction","volume":"233","author":"Marques","year":"2019","journal-title":"Life Sci"},{"key":"2024083002381189000_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13578-020-00500-5","article-title":"Iron accumulation in macrophages promotes the formation of foam cells and development of atherosclerosis","volume":"10","author":"Cai","year":"2020","journal-title":"Cell Biosci"},{"key":"2024083002381189000_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/ars.2020.8167","article-title":"Non-transferrin-bound iron in the spotlight: novel mechanistic insights into the vasculotoxic and atherosclerotic effect of iron","volume":"35","author":"Vinchi","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"2024083002381189000_bib27","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/eurheartj\/ehz112","article-title":"Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction","volume":"41","author":"Vinchi","year":"2020","journal-title":"Eur Heart J"},{"key":"2024083002381189000_bib28","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/s41598-022-10717-8","article-title":"Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart trial","volume":"12","author":"Kassianides","year":"2022","journal-title":"Sci Rep"},{"key":"2024083002381189000_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/antiox8100498","article-title":"Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease","volume":"8","author":"Nuhu","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"2024083002381189000_bib30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40620-020-00885-z","article-title":"Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease","volume":"34","author":"Cozzolino","year":"2021","journal-title":"J Nephrol"},{"key":"2024083002381189000_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ckj\/sfaa135","article-title":"The emerging role of iron in heart failure and vascular calcification in CKD","volume":"14","author":"Ciceri","year":"2020","journal-title":"Clin Kidney J"},{"key":"2024083002381189000_bib32","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.3390\/ijms20235925","article-title":"Therapeutic effect of iron citrate in blocking calcium deposition in high pi-calcified VSMC: role of autophagy and apoptosis","volume":"20","author":"Ciceri","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024083002381189000_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijcard.2019.09.068","article-title":"High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs","volume":"297","author":"Ciceri","year":"2019","journal-title":"Int J Cardiol"},{"key":"2024083002381189000_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/0886022X.2021.1880937","article-title":"Iron, coronary artery calcification, and mortality in patients undergoing hemodialysis","volume":"43","author":"Mizuiri","year":"2021","journal-title":"Ren Fail"},{"key":"2024083002381189000_bib35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00223-020-00804-1","article-title":"Iron sucrose: a double-edged sword in high phosphate media-induced vascular calcification","volume":"108","author":"Wang","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"2024083002381189000_bib36","first-page":"282","article-title":"The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption","volume-title":"Cell Metab","author":"Anderson","year":"2013"},{"key":"2024083002381189000_bib37","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"2024083002381189000_bib38","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J Clin Invest"},{"key":"2024083002381189000_bib39","doi-asserted-by":"crossref","first-page":"e7875","DOI":"10.1371\/journal.pone.0007875","article-title":"Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors","volume":"4","author":"Volke","year":"2009","journal-title":"PLoS One"},{"key":"2024083002381189000_bib40","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1074\/jbc.M110.173096","article-title":"Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis","volume":"286","author":"Lakhal","year":"2011","journal-title":"J Biol Chem"},{"key":"2024083002381189000_bib41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-021-00696-z","article-title":"New regulators of systemic iron homeostasis","volume":"6","author":"Ganz","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2024083002381189000_bib42","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"2024083002381189000_bib43","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1093\/nar\/27.21.4223","article-title":"HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation","volume":"27","author":"Bianchi","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"2024083002381189000_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOH.0000000000000494","article-title":"New insights into the links between hypoxia and iron homeostasis","volume":"26","author":"Renassia","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"2024083002381189000_bib45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.seminhematol.2009.06.004","article-title":"Recycling iron in normal and pathological states","volume":"46","author":"Beaumont","year":"2009","journal-title":"Semin Hematol"},{"key":"2024083002381189000_bib46","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.lfs.2004.03.027","article-title":"Regulation of ferrochelatase gene expression by hypoxia","volume":"75","author":"Liu","year":"2004","journal-title":"Life Sci"},{"key":"2024083002381189000_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/BJ20091609","article-title":"Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents","volume":"427","author":"Flashman","year":"2010","journal-title":"Biochem J"},{"key":"2024083002381189000_bib48","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/ckj\/sfad105","article-title":"The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors","volume":"16","author":"Locatelli","year":"2023","journal-title":"Clin Kidney J"},{"key":"2024083002381189000_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"van Haalen","year":"2020","journal-title":"BMC Nephrol"},{"key":"2024083002381189000_bib50","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/M15-1839","article-title":"The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis","volume":"164","author":"Collister","year":"2016","journal-title":"Ann Intern Med"},{"key":"2024083002381189000_bib51","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"2024083002381189000_bib52","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2024083002381189000_bib53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12882-020-01912-8","article-title":"Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis","volume":"21","author":"Guedes","year":"2020","journal-title":"BMC Nephrol"},{"key":"2024083002381189000_bib54","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"Am Soc Nephrol"},{"key":"2024083002381189000_bib55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2174\/1570161120666220527093551","article-title":"The relation between red blood cell distribution width and coronary atherosclerotic plaque vulnerability detected by intracoronary optical coherence tomography","volume":"20","author":"Jin","year":"2022","journal-title":"Curr Vasc Pharmacol"},{"key":"2024083002381189000_bib56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ndt\/gfu104","article-title":"Iron dosing in kidney disease: inconsistency of evidence and clinical practice","volume":"30","author":"Gaweda","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2024083002381189000_bib57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","article-title":"Iron status in patients with chronic heart failure","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2024083002381189000_bib58","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"2024083002381189000_bib59","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"key":"2024083002381189000_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"2024083002381189000_bib61","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL Trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024083002381189000_bib62","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2024083002381189000_bib63","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2024083002381189000_bib64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/eurheartj\/ehi696","article-title":"Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis","volume":"27","author":"de Silva","year":"2006","journal-title":"Eur Heart J"},{"key":"2024083002381189000_bib65","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurheartj\/ehac825","article-title":"Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study","volume":"44","author":"Mark","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002381189000_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure: an overview","volume":"7","author":"von Haehling","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2024083002381189000_bib67","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"2024083002381189000_bib68","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/ejhf.412","article-title":"Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease","volume":"17","author":"Bello","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2024083002381189000_bib69","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2024083002381189000_bib70","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","volume":"19","author":"Melenovsky","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2024083002381189000_bib71","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"2024083002381189000_bib72","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2024083002381189000_bib73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2024083002381189000_bib74","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"2024083002381189000_bib75","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12882-021-02308-y","article-title":"A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric derisomaltose (FDI)) in iron deficient but not anaemic patients with chronic kidney disease on functional status","volume":"22","author":"Bhandari","year":"2021","journal-title":"BMC Nephrol"},{"key":"2024083002381189000_bib76","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2024083002381189000_bib77","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2024083002381189000_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2024083002381189000_bib79","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jchf.2021.04.005","article-title":"Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy","volume":"9","author":"Jhund","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2024083002381189000_bib80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/cvr\/cvab317","article-title":"High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis","volume":"119","author":"Petrie","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2024083002381189000_bib81","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024083002381189000_bib82","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2459\/JCM.0000000000001543","article-title":"Prognostic impact of red blood cell distribution width in chronic heart failure patients with left ventricular dysfunction","volume":"24","author":"Ferreira","year":"2023","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2024083002381189000_bib83","doi-asserted-by":"crossref","first-page":"102273","DOI":"10.1016\/j.eclinm.2023.102273","article-title":"Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial","volume":"65","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2024083002381189000_bib84","doi-asserted-by":"crossref","first-page":"116008","DOI":"10.1016\/j.bcp.2023.116008","article-title":"Thrombopoietin treats erythropoietin resistance by correcting EPO-induced progenitorcell depletion","volume":"220","author":"Zou","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2024083002381189000_bib85","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"key":"2024083002381189000_bib86","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1208\/s12248-016-9886-1","article-title":"Pharmacodynamic model of hepcidin regulation of iron homeostasis in cynomolgus monkeys","volume":"18","author":"Krzyzanski","year":"2016","journal-title":"AAPS J"},{"key":"2024083002381189000_bib87","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.2019004653","article-title":"A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease","volume":"136","author":"Petzer","year":"2020","journal-title":"Blood"},{"key":"2024083002381189000_bib88","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.3324\/haematol.2015.140772","article-title":"Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels","volume":"101","author":"Kovac","year":"2016","journal-title":"Haematologica"},{"key":"2024083002381189000_bib89","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/ajh.26961","article-title":"FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes","volume":"98","author":"Pettinato","year":"2023","journal-title":"Am J Hematol"},{"key":"2024083002381189000_bib90","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"key":"2024083002381189000_bib91","doi-asserted-by":"crossref","first-page":"173958","DOI":"10.1016\/j.ejphar.2021.173958","article-title":"Low anticoagulant heparin-iron complex targeting inhibition of hepcidin ameliorates anemia of chronic disease in rodents","volume":"897","author":"Li","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"2024083002381189000_bib92","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2023-181587","article-title":"The heparinoid sevuparin improves anemia and kidney status in a mouse model of chronic kidney disease","volume":"142","author":"Asperti","year":"2023","journal-title":"Blood"},{"key":"2024083002381189000_bib93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.kint.2023.04.017","article-title":"Deregulating iron-erythropoiesis regulation: transferrin receptor 2 as potential target for treating anemia in CKD","volume":"104","author":"Koury","year":"2023","journal-title":"Kidney Int"},{"key":"2024083002381189000_bib94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.kint.2023.03.012","article-title":"A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease","volume":"104","author":"Olivari","year":"2023","journal-title":"Kidney Int"},{"key":"2024083002381189000_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1681\/ASN.2020050595","article-title":"Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024083002381189000_bib96","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2024083002381189000_bib97","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1038\/s41598-021-85778-2","article-title":"Experimental modulation of interleukin 1 shows its key role in chronic kidney disease progression and anemia","volume":"11","author":"Bandach","year":"2021","journal-title":"Sci Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae095\/58515667\/gfae095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/9\/1404\/58962984\/gfae095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/9\/1404\/58962984\/gfae095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T22:38:52Z","timestamp":1724971132000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/9\/1404\/7657798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":97,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,4,24]]},"published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae095","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,24]]}}}